Skip to main content
Top
Published in: Clinical Research in Cardiology 9/2019

01-09-2019 | Acute Lymphoblastic Leukemia | Original Paper

Doxorubicin treatments induce significant changes on the cardiac autonomic nervous system in childhood acute lymphoblastic leukemia long-term survivors

Authors: Maxime Caru, Denis Corbin, Delphine Périé, Valérie Lemay, Jacques Delfrate, Simon Drouin, Laurence Bertout, Maja Krajinovic, Caroline Laverdière, Gregor Andelfinger, Daniel Sinnett, Daniel Curnier

Published in: Clinical Research in Cardiology | Issue 9/2019

Login to get access

Abstract

Aims

Acute lymphoblastic leukemia (ALL) is one of the leading malignancies in children worldwide. The cardiotoxicity of anti-cancer treatments leads to a dysfunction of the cardiac autonomic nervous system. Protection strategies, with dexrazoxane treatments, were used to counter these adverse effects. The aim of this study was to investigate the effects of the treatments on the cardiac autonomic nervous system.

Methods and results

A total of 203 cALL survivors were included in our analyses and were classified into 3 categories based on the prognostic risk group: standard risk, high risk with and without dexrazoxane. A 24-h Holter monitoring was performed to study the cardiac autonomic nervous system. The frequency domain heart rate variability (HRV) was used to validate the cardiac autonomic nervous system modifications. Other analyses were performed using linear HRV indexes in the time domain and non-linear indexes. A frequency domain HRV parameters analysis revealed significant differences on an overall time-period of 24 h. A repeated measures ANOVA indicated a group-effect for the low frequency (p = 0.029), high frequency (p = 0.03) and LF/HF ratio (p = 0.029). Significant differences in the time domain and in the non-linear power spectral density HRV parameters were also observed.

Conclusion

Anti-cancer treatments induced significant changes in the cardiac autonomic nervous system. The HRV was sensitive enough to detect cardiac autonomic nervous system alterations depending on the cALL risk category. Protection strategies (i.e., dexrazoxane treatments), which were used to counter the adverse effects of doxorubicin, could prevent changes observed in the cardiac autonomic nervous system.
Literature
1.
go back to reference Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabro R (2005) Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr Drugs 7(2):67–76CrossRefPubMed Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabro R (2005) Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr Drugs 7(2):67–76CrossRefPubMed
9.
go back to reference Viniegra M, Marchetti M, Losso M, Navigante A, Litovska S, Senderowicz A, Borghi L, Lebron J, Pujato D, Marrero H et al (1990) Cardiovascular autonomic function in anthracycline-treated breast cancer patients. Cancer Chemother Pharmacol 26(3):227–231CrossRefPubMed Viniegra M, Marchetti M, Losso M, Navigante A, Litovska S, Senderowicz A, Borghi L, Lebron J, Pujato D, Marrero H et al (1990) Cardiovascular autonomic function in anthracycline-treated breast cancer patients. Cancer Chemother Pharmacol 26(3):227–231CrossRefPubMed
12.
go back to reference Kamath MV, Halton J, Harvey A, Turner-Gomes S, McArthur A, Barr RD (1998) Cardiac autonomic dysfunction in survivors of acute lymphoblastic leukemia in childhood. Int J Oncol 12(3):635–640PubMed Kamath MV, Halton J, Harvey A, Turner-Gomes S, McArthur A, Barr RD (1998) Cardiac autonomic dysfunction in survivors of acute lymphoblastic leukemia in childhood. Int J Oncol 12(3):635–640PubMed
13.
go back to reference Silverman LB, Stevenson KE, O’Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O’Holleran EW, Neuberg DS, Cohen HJ, Sallan SE (2010) Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia 24(2):320–334. https://doi.org/10.1038/leu.2009.253 CrossRefPubMed Silverman LB, Stevenson KE, O’Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O’Holleran EW, Neuberg DS, Cohen HJ, Sallan SE (2010) Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia 24(2):320–334. https://​doi.​org/​10.​1038/​leu.​2009.​253 CrossRefPubMed
14.
go back to reference Marcoux S, Drouin S, Laverdiere C, Alos N, Andelfinger GU, Bertout L, Curnier D, Friedrich MG, Kritikou EA, Lefebvre G, Levy E, Lippe S, Marcil V, Raboisson MJ, Rauch F, Robaey P, Samoilenko M, Seguin C, Sultan S, Krajinovic M, Sinnett D (2017) The PETALE study: late adverse effects and biomarkers in childhood acute lymphoblastic leukemia survivors. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.26361 CrossRefPubMed Marcoux S, Drouin S, Laverdiere C, Alos N, Andelfinger GU, Bertout L, Curnier D, Friedrich MG, Kritikou EA, Lefebvre G, Levy E, Lippe S, Marcil V, Raboisson MJ, Rauch F, Robaey P, Samoilenko M, Seguin C, Sultan S, Krajinovic M, Sinnett D (2017) The PETALE study: late adverse effects and biomarkers in childhood acute lymphoblastic leukemia survivors. Pediatr Blood Cancer. https://​doi.​org/​10.​1002/​pbc.​26361 CrossRefPubMed
15.
go back to reference Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ (1981) Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 213(4504):220–222CrossRefPubMed Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ (1981) Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 213(4504):220–222CrossRefPubMed
16.
go back to reference Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93(5):1043–1065CrossRef Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93(5):1043–1065CrossRef
17.
go back to reference Arab C, Vanderlei LCM, da Silva Paiva L, Fulghum KL, Fristachi CE, Nazario ACP, Elias S, Gebrim LH, Ferreira Filho C, Gidron Y (2018) Cardiac autonomic modulation impairments in advanced breast cancer patients. Clin Res Cardiol 107(10):924–936CrossRefPubMed Arab C, Vanderlei LCM, da Silva Paiva L, Fulghum KL, Fristachi CE, Nazario ACP, Elias S, Gebrim LH, Ferreira Filho C, Gidron Y (2018) Cardiac autonomic modulation impairments in advanced breast cancer patients. Clin Res Cardiol 107(10):924–936CrossRefPubMed
18.
go back to reference Berntson GG, Bigger JT Jr, Eckberg DL, Grossman P, Kaufmann PG, Malik M, Nagaraja HN, Porges SW, Saul JP, Stone PH, van der Molen MW (1997) Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology 34(6):623–648CrossRefPubMed Berntson GG, Bigger JT Jr, Eckberg DL, Grossman P, Kaufmann PG, Malik M, Nagaraja HN, Porges SW, Saul JP, Stone PH, van der Molen MW (1997) Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology 34(6):623–648CrossRefPubMed
19.
21.
go back to reference Heart rate variability (1996) Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Euro Heart J 17(3):354–381CrossRef Heart rate variability (1996) Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Euro Heart J 17(3):354–381CrossRef
22.
go back to reference Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29(4):277–314. https://doi.org/10.1016/j.echo.2016.01.011 CrossRef Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29(4):277–314. https://​doi.​org/​10.​1016/​j.​echo.​2016.​01.​011 CrossRef
23.
24.
go back to reference Myerburg RJ, Kessler KM, Luceri RM, Zaman L, Trohman RG, Estes D, Castellanos A (1984) Classification of ventricular arrhythmias based on parallel hierarchies of frequency and form. Am J Cardiol 54(10):1355–1358CrossRefPubMed Myerburg RJ, Kessler KM, Luceri RM, Zaman L, Trohman RG, Estes D, Castellanos A (1984) Classification of ventricular arrhythmias based on parallel hierarchies of frequency and form. Am J Cardiol 54(10):1355–1358CrossRefPubMed
25.
go back to reference Lown B, Wolf M (1971) Approaches to sudden death from coronary heart disease. Circulation 44(1):130–142CrossRef Lown B, Wolf M (1971) Approaches to sudden death from coronary heart disease. Circulation 44(1):130–142CrossRef
26.
go back to reference Bethge K-P (1991) Classification of arrhythmias. J Cardiovasc Pharmacol 17:S20CrossRef Bethge K-P (1991) Classification of arrhythmias. J Cardiovasc Pharmacol 17:S20CrossRef
27.
go back to reference Nevruz O, Yokusoglu M, Uzun M, Demirkol S, Avcu F, Baysan O, Koz C, Cetin T, Sag C, Ural AU, Isik E (2007) Cardiac autonomic functions are altered in patients with acute leukemia, assessed by heart rate variability. Tohoku J Exp Med 211(2):121–126CrossRefPubMed Nevruz O, Yokusoglu M, Uzun M, Demirkol S, Avcu F, Baysan O, Koz C, Cetin T, Sag C, Ural AU, Isik E (2007) Cardiac autonomic functions are altered in patients with acute leukemia, assessed by heart rate variability. Tohoku J Exp Med 211(2):121–126CrossRefPubMed
31.
go back to reference Kamath MV, Fallen EL (1993) Power spectral analysis of heart rate variability: a noninvasive signature of cardiac autonomic function. Crit Rev Biomed Eng 21(3):245–311PubMed Kamath MV, Fallen EL (1993) Power spectral analysis of heart rate variability: a noninvasive signature of cardiac autonomic function. Crit Rev Biomed Eng 21(3):245–311PubMed
32.
go back to reference van Bilsen M, Patel HC, Bauersachs J, Bohm M, Borggrefe M, Brutsaert D, Coats AJS, de Boer RA, de Keulenaer GW, Filippatos GS, Floras J, Grassi G, Jankowska EA, Kornet L, Lunde IG, Maack C, Mahfoud F, Pollesello P, Ponikowski P, Ruschitzka F, Sabbah HN, Schultz HD, Seferovic P, Slart R, Taggart P, Tocchetti CG, Van Laake LW, Zannad F, Heymans S, Lyon AR (2017) The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 19(11):1361–1378. https://doi.org/10.1002/ejhf.921 CrossRefPubMed van Bilsen M, Patel HC, Bauersachs J, Bohm M, Borggrefe M, Brutsaert D, Coats AJS, de Boer RA, de Keulenaer GW, Filippatos GS, Floras J, Grassi G, Jankowska EA, Kornet L, Lunde IG, Maack C, Mahfoud F, Pollesello P, Ponikowski P, Ruschitzka F, Sabbah HN, Schultz HD, Seferovic P, Slart R, Taggart P, Tocchetti CG, Van Laake LW, Zannad F, Heymans S, Lyon AR (2017) The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 19(11):1361–1378. https://​doi.​org/​10.​1002/​ejhf.​921 CrossRefPubMed
33.
go back to reference Fradley MG, Viganego F, Kip K, Martin A, Patel AA, Ismail-Khan R, Chae S, Herweg B, Labovitz A (2017) Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies. Open Heart 4(2):e000701CrossRefPubMedPubMedCentral Fradley MG, Viganego F, Kip K, Martin A, Patel AA, Ismail-Khan R, Chae S, Herweg B, Labovitz A (2017) Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies. Open Heart 4(2):e000701CrossRefPubMedPubMedCentral
36.
go back to reference Benjamin EJ, Levy D, Vaziri SM, D’agostino RB, Belanger AJ, Wolf PA (1994) Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. Jama 271(11):840–844CrossRefPubMed Benjamin EJ, Levy D, Vaziri SM, D’agostino RB, Belanger AJ, Wolf PA (1994) Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. Jama 271(11):840–844CrossRefPubMed
37.
go back to reference Poreba M, Poreba R, Gac P, Usnarska-Zubkiewicz L, Pilecki W, Piotrowicz E, Piotrowicz R, Rusiecki L, Kuliczkowski K, Mazur G, Sobieszczanska M (2014) Heart rate variability and heart rate turbulence in patients with hematologic malignancies subjected to high-dose chemotherapy in the course of hematopoietic stem cell transplantation. Ann Noninvasive Electrocardiol 19(2):157–165. https://doi.org/10.1111/anec.12108 CrossRefPubMed Poreba M, Poreba R, Gac P, Usnarska-Zubkiewicz L, Pilecki W, Piotrowicz E, Piotrowicz R, Rusiecki L, Kuliczkowski K, Mazur G, Sobieszczanska M (2014) Heart rate variability and heart rate turbulence in patients with hematologic malignancies subjected to high-dose chemotherapy in the course of hematopoietic stem cell transplantation. Ann Noninvasive Electrocardiol 19(2):157–165. https://​doi.​org/​10.​1111/​anec.​12108 CrossRefPubMed
38.
42.
go back to reference Faber J, Wingerter A, Neu MA, Henninger N, Eckerle S, Münzel T, Lackner KJ, Beutel ME, Blettner M, Rathmann W, Peters A, Meisinger C, Linkohr B, Neuhauser H, Kaatsch P, Spix C, Schneider A, Merzenich H, Panova-Noeva M, Prochaska JH, Wild PS (2018) Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study. Eur Heart J 39(17):1555–1562. https://doi.org/10.1093/eurheartj/ehy026 CrossRefPubMed Faber J, Wingerter A, Neu MA, Henninger N, Eckerle S, Münzel T, Lackner KJ, Beutel ME, Blettner M, Rathmann W, Peters A, Meisinger C, Linkohr B, Neuhauser H, Kaatsch P, Spix C, Schneider A, Merzenich H, Panova-Noeva M, Prochaska JH, Wild PS (2018) Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study. Eur Heart J 39(17):1555–1562. https://​doi.​org/​10.​1093/​eurheartj/​ehy026 CrossRefPubMed
43.
go back to reference Packer M (1998) Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Progr Cardiovasc Dis 41(1 Suppl 1):39–52CrossRef Packer M (1998) Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Progr Cardiovasc Dis 41(1 Suppl 1):39–52CrossRef
47.
go back to reference Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdiere C, Michon B, Schorin MA, Sallan SE (2012) Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 30(10):1042–1049. https://doi.org/10.1200/jco.2010.30.3404 CrossRefPubMedPubMedCentral Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdiere C, Michon B, Schorin MA, Sallan SE (2012) Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 30(10):1042–1049. https://​doi.​org/​10.​1200/​jco.​2010.​30.​3404 CrossRefPubMedPubMedCentral
50.
go back to reference Riffel JH, Keller MG, Aurich M, Sander Y, Andre F, Giusca S, Aus dem Siepen F, Seitz S, Galuschky C, Korosoglou G, Mereles D, Katus HA, Buss SJ (2015) Assessment of global longitudinal strain using standardized myocardial deformation imaging: a modality independent software approach. Clin Res Cardiol 104(7):591–602. https://doi.org/10.1007/s00392-015-0822-7 CrossRefPubMed Riffel JH, Keller MG, Aurich M, Sander Y, Andre F, Giusca S, Aus dem Siepen F, Seitz S, Galuschky C, Korosoglou G, Mereles D, Katus HA, Buss SJ (2015) Assessment of global longitudinal strain using standardized myocardial deformation imaging: a modality independent software approach. Clin Res Cardiol 104(7):591–602. https://​doi.​org/​10.​1007/​s00392-015-0822-7 CrossRefPubMed
Metadata
Title
Doxorubicin treatments induce significant changes on the cardiac autonomic nervous system in childhood acute lymphoblastic leukemia long-term survivors
Authors
Maxime Caru
Denis Corbin
Delphine Périé
Valérie Lemay
Jacques Delfrate
Simon Drouin
Laurence Bertout
Maja Krajinovic
Caroline Laverdière
Gregor Andelfinger
Daniel Sinnett
Daniel Curnier
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 9/2019
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-019-01427-9

Other articles of this Issue 9/2019

Clinical Research in Cardiology 9/2019 Go to the issue